Boai NKY Medical Holdings (SZSE:300109) ROCE % : 11.96% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Boai NKY Medical Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Boai NKY Medical Holdings's annualized ROCE % for the quarter that ended in Sep. 2024 was 11.96%.

Boai NKY Medical Holdings ROCE % Historical Data

The historical data trend for Boai NKY Medical Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boai NKY Medical Holdings ROCE % Chart

Boai NKY Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

9.18

3.72

9.93

11.83

17.27

Boai NKY Medical Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															21.83	7.36	15.77	12.11	11.96

Boai NKY Medical Holdings ROCE % Calculation

Boai NKY Medical Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	587.427	/	( ( (3713.698 - 502.029)	+	(4019.691 - 426.948) )	/ 2 )
	=	587.427	/	( (3211.669	+	3592.743)	/ 2 )
	=	587.427	/	3402.206
	=	17.27 %

Boai NKY Medical Holdings's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	438.328	/	( ( (4411.08 - 773.21)	+	(4304.209 - 613.384) )	/ 2 )
	=	438.328	/	( ( 3637.87	+	3690.825 )	/ 2 )
	=	438.328	/	3664.3475
	=	11.96 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Boai NKY Medical Holdings (SZSE:300109) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Boai NKY Medical Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Boai NKY Medical Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Boai NKY Medical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Boai NKY Medical Holdings Ltd (SZSE:300109) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1888, Wenhua Road (East Section), Boai county, Henan Province, Jiaozuo, CHN, 454450

Website

http://www.nkygroup.cn

Boai NKY Medical Holdings Ltd is engaged in Research and development, production of pharmaceutical excipients, APIs (povidone-iodine), adhesives, food additives (insoluble polyvinyl polypyrrolidone); polyvinyl pyrrolidone series products, vinyl methyl ether/maleic anhydride polymers.

Executives

Li She Gang	Executives
Zou Xiao Wen	Executives
Zhang Jun Zheng	Directors, executives
Yang Hong Bo	Director
Wang Dong Hu	Director
Ren Da Long	Director
Xing Xiao Liang	Directors, executives
Wang Shi Gang	Executives
Wang Xin Meng	Executives
Qu Yun Xia	Supervisors
Wang Jian Qiang	Director
Yang Hai Jiang	Director
Yan Zhong Chao	Supervisors
Liu Ai Min	Executives
Wu Cong Zhou	Executives

Boai NKY Medical Holdings Headlines

No Headlines